The company said the partnership aims to leverage Broadway’s technical expertise, manufacturing capabilities, distribution, and market reach to fast-track the commercialization of Black Swan’s graphene products.
Broadway will use Black Swan’s graphene nanoplatelets to manufacture their Graphene Enhanced Masterbatches (GEMs) targeting a variety of sectors including consumer goods, packaging, automotive, construction, defense, marine and logistics.
Its new product range will also feature a bio-based polymer GEM, which Black Swan highlighted offers an eco-friendly alternative to the existing products.
The two companies will use their commercial teams to advocate for the benefits of GEMs in global markets, with the agreement including provisions for joint marketing initiatives to promote each company’s eco-friendly products.
“We are excited to partner with Broadway, a trusted name in the masterbatch manufacturing industry,” Black Swan CEO Simon Marcotte said in a statement.
“This collaboration will enhance our ability to deliver high-performance graphene-enhanced products to a broader market, accelerating their adoption as we continue to roll out our commercialization efforts in Europe, North America and internationally."
Broadway founder Joe Maynard also expressed his enthusiasm about the partnership.
“We are excited to bring cost-efficient graphene-enhanced masterbatches to market by integrating Black Swan's advanced graphene into our formulations, driving innovation, and meeting the evolving needs of various industries,” Maynard said.
Read the original article on Proactive Investors.
